Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Colleen GC McGregor; Alex Adams; Ross Sadler; Carolina V Arancibia-Cárcamo; Rebecca Palmer; Tim Ambrose; Oliver Brain; Alissa Walsh; Paul Klenerman; Simon PL Travis; Nicholas M Croft; James O Lindsay; Jack Satsangi

doi:10.1136/gutjnl-2021-324116

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Hosted content
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PostScript

Letter

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password